New treatment options in onychomycosis Jan Faergemann, M.D., Ph.D., Professor **Department of Dermatology** Sahlgrenska University Hospital Gothenburg Sweden

Fungi involved in Onychomycosis (Summerbell, et al, 1989)

- Trichophyton rubrum 71 %
- T. mentagrophytes 20 %
- Candida albicans 5.6 %
- Scopulariopsis brevicaulis 1.7 %
- Other moulds 1.7 %

- The most prevalent disease of the nails
- 50 % of all nail disturbances
- 10 30 % of all dermatophytoses
- 3 to 30 % of the population are affected
- Increases steadily with the age of the individual

Predisposing factors in onychomycosis

- The age of the individual
- Hereditary factors dominant inheritage
- Diabetes mellitus
- Immunosuppression
- Vascular disease
- Occlusive footwear
- Psoriasis

Age distribution of Onychomycosis (Gupta, et al, 1997)

- 0 10 years: 2.3 %
- 20 30 years: 6.9 %
- 40 50 years: 24.1 %
- 60 70 years: 40.0 %
- > 80 years: 61.5 %

Prevalence of onychomycosis

- Range 3 to 30 % depending on methodology and predisposing factors
- Questionaire: 2.7 % (Roberts, 1992)
- Clin + Mycology: 9. 1 % (Gupta et al., 1997)
- Clin + Mycology: 36 46 % (Haneke and Roseeuw, 1999)
- Clin + Mycology: 8 % (Gupta, et al., 2000)

Diagnosis of onychomycosis

- A correct sampling technique is very important
- Scrape the debris under the nail with a small (2 mm) curette at the border between normal and diseased nail.
- Combine the material with nails clippings

Diagnosis of onychomycosis

- Direct microscopy: KOH, Calcoflour white
- Culture



Differential diagnosis

- Psoriasis
- Lichen planus
- Nail dystrophia

Major Clinical Presentations

Distal subungal types • Distal lateral subungal Endonyx Proximal subungal Superficial types Total dystrophic types Primary Secondary



Major Clinical Presentations

- Distal subungal types
 - ⁻ Distal lateral subungal
 - ⁻ Endonyx
- Proximal subungal
- Superficial types
- Total dystrophic types
 - ⁻ Primary
 - ⁻ Secondary



Major Clinical Presentations

- Distal subungal types
 - ⁻ Distal lateral subungal
 - ⁻ Endonyx
- Proximal subungal
- Superficial types
- Total dystrophic types
 - ⁻ Primary
 - ⁻ Secondary



Major Clinical Presentations

Distal subungal types ⁻ Distal lateral subungal ⁻ Endonyx Proximal subungal Superficial types Total dystrophic types Primary Secondary



Major Clinical Presentations

- Distal subungal types ⁻ Distal lateral subungal
 - ⁻ Endonyx
- Proximal subungal
- Superficial types
- Total dystrophic types
 - ⁻ Primary
 - ⁻ Secondary



Major Clinical Presentations

- Distal subungal types
 Distal lateral subungal
 - ⁻ Endonyx
- Proximal subungal
- Superficial types
- Total dystrophic types
 - ⁻ Primary
 - Secondary



Treatment of Onychomycosis

- Oral treatment
- Topical treatment
- Combined oral and topical treatment

L.I.O.N. study

Evans EGV, Sigurgeirsson B et al. BMJ 1999;518:1031-1035

Terbinafine versus itraconazole in onychomycosis of toenails

- Terbinafine 250 mg daily for 12 weeks (T 12) and 16 weeks (T 16)
- Itraconazole 400 mg daily, one week per month for 3 months (I 3) and 4 months (I 4)
- Design: Double-blind, parallel group

Mycological Results (72 weeks)

- 76 % (81/107) in T12 group
- 81 % (80/99) in T16 group
- 38 % 41/107) in I 3 group
- 49 % (53/108) in I 4 group

Complete cure (72 weeks)

- 46 % (49/107) in T 12 group
- 55 % (54/98) in T 16 group
- 23 % (29/102) in I 3 group
- 26 % 28/108) in I 4 group

Once-Weekly 5% Nail Lacquer Results in Good Mycological/Clinical Efficacy at Study End



Reinel, 1992

Do We Need Combination Therapy for Onychomycosis with Matrix Involvement?

- 25-50% of patients given oral monotherapy fail treatment or relapse
- Complementary routes of drug penetration may be helpful
 - Topical drugs penetrate via nail plate
 - Oral drugs penetrate the nail bed
- Drug combination can result in drug synergy (increased efficacy at lower drug concentrations)
- Drug combination may be of use in the treatment of onychomycosis with matrix involvement (severe cases)

Combination with Oral Terbinafine for Onychomycosis with Matrix Involvement - Study Design



Baran *et al*, 2000

Combination with Oral Terbinafine for Onychomycosis with Matrix Involvement - Mycological/Clinical Efficacy at 18 Months



Combination with Oral Terbinafine for Onychomycosis with Matrix Involvement - Case 1



A: baseline

B: 3 months

C: 12 months

Combination with Oral Itraconazole for Onychomycosis with Matrix Involvement - Study Design



KEY ■ Itraconazole 200 mg once daily ■ Loceryl® Nail Lacquer once weekly

Lecha *et al*, 2001

Combination with Oral Itraconazole for Onychomycosis with Matrix Involvement - Mycological/Clinical Efficacy after 6 Months



* P<0.05 compared with I-12 group

Lecha *et al*, 2001

Combination with Oral Itraconazole for Onychomycosis with Matrix Involvement - Case 1







A: baseline

B: 3 months

C: 6 months

Specific Problems in the Treatment of Onychomycosis

- Mycological cure rates (70 %) versus clinical cure rates (45-60%)
- Failures!
- How do clinical trial results translate into long term results in every day practice
- Recurrences

Drug resistance

- Rare with dermatophytes
- Rare with common Candida infections
- Vary with different Candida species e. g. C. tropicalis, C. krusei, C. glabrata

TOE-Consensus on treatment strategies

- Taskforce on Onychomycosis Education. JEADV 2005;19:Suppl 1
- Three main treatment strategies are recognized: oral, topical and combination

TOE-Consensus on treatment strategies

- Topical mono therapy is recommended in absence of matrix involvement
- Oral mono therapy or combination therapy is indicated when the matrix area is involved
- Combination therapy appears to be an effective treatment approach

TOE-Consensus on treatment strategies

- Chemical or mechanical treatment is indicated when drug transport is suboptimal with systemic drugs
- Need for decision-making tools; e. g. a CD-ROM or booklet presenting each type of onychomycosis and criteria to be considered before selecting treatment regimen.

Conclusion

- Onychomycosis is a common disease affecting 3 to 30 % of the population
- Predisposing factors are important
- A correct sampling technique is mandatory for a correct diagnosis
- Complete cure with oral treatment is 40
 50 %
- Combination therapy with oral and topical therapy will increase cure rates